Akebia Therapeutics (AKBA)
NASDAQ:AKBA

Akebia Therapeutics Stock Analysis & Ratings

Akebia Therapeutics Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Akebia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

AKBA

AKBA Stock Stats

Previous Close$2.04
Open$2.02
Bid1.98 x 200
Ask1.99 x 200
Today’s Range$1.99 - $2.09
52-Week Range$1.99 - $5.14
Volume4.42M
Average Volume2.60M
Market Cap$349.92M
Beta1.50
P/E Ratio-1.0
EPS-1.91
Earnings DateMar 14, 2022

Company Description

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Sector
Healthcare
Industry
Biotechnology
CEO
John P. Butler
Employees
380
Website
http://www.akebia.com
ISIN
US00972D1054
Address
245 First Street, Cambridge, MA, 02142, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

AKBA FAQ

What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $1.99 and its highest was $5.14 in the past 12 months.
    What is Akebia Therapeutics’s market cap?
    Akebia Therapeutics’s market cap is $349.92M.
      What is Akebia Therapeutics’s price target?
      The average price target for Akebia Therapeutics is $6.44. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $10.00 ,the lowest forecast is $2.75. The average price target represents 222.00% Increase from the current price of $2.
        What do analysts say about Akebia Therapeutics?
        Akebia Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Akebia Therapeutics’s upcoming earnings report date?
          Akebia Therapeutics’s upcoming earnings report date is Mar 14, 2022 which is in 48 days.
            How were Akebia Therapeutics’s earnings last quarter?
            Akebia Therapeutics released its earnings results on Nov 04, 2021. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.02.
              Is Akebia Therapeutics overvalued?
              According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
                Does Akebia Therapeutics pay dividends?
                Akebia Therapeutics does not currently pay dividends.
                What is Akebia Therapeutics’s EPS estimate?
                Akebia Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Akebia Therapeutics have?
                Akebia Therapeutics has 174,960,000 shares outstanding.
                  What happened to Akebia Therapeutics’s price movement after its last earnings report?
                  Akebia Therapeutics reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -12.275%.
                    Which hedge fund is a major shareholder of Akebia Therapeutics?
                    Among the largest hedge funds holding Akebia Therapeutics’s share is Maverick Capital ltd. It holds Akebia Therapeutics’s shares valued at 305K.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis